Markt oder Branche auswählen:
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| BIONTECH | 5 | 13 | -0,18 % | ||
| MODERNA | 1 | 16 | +0,48 % | ||
| GILEAD SCIENCES | 1 | 5 | -0,61 % | ||
| REVOLUTION MEDICINES | 1 | 5 | +0,72 % | ||
| VIATRIS | 1 | 2 | -0,82 % | ||
| BIOGEN | - | 54 | +0,08 % | ||
| AMGEN | - | 27 | -0,52 % | ||
| INCYTE | - | 25 | -0,68 % | ||
| REGENERON PHARMACEUTICALS | - | 22 | 0,00 % | ||
| MONTE ROSA THERAPEUTICS | - | 21 | 0,00 % |
- 24 h
- 7 Tage
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 01:27 | Revolution Medicines Is Up Nearly 140% in 2026. Is the Hot Biotech Stock Still a Buy? | 3 | The Motley Fool | ||
| 01:26 | R&D Change Underlines Sanofi SA (SNY) Prospects as One of the Best Dividend Stocks to Buy | 3 | Insider Monkey | ||
| So | Viatris (VTRS): Most Undervalued NASDAQ Stocks to Buy Right Now | 7 | Insider Monkey | ||
| So | BioNTech Aktie: 1.800 Jobs wackeln und Moderna greift zu | 1.106 | börsennews.de | BioNTech steht vor einem tiefen Umbau. Der einstige Hoffnungsträger der deutschen Biotechbranche muss Werke schließen, Stellen streichen und seine Zukunft neu ausrichten. Für Anleger rückt damit die... ► Artikel lesen | |
| So | Curevac im Blickpunkt: Warum Insider bereits reagiert haben - Meine klare Einschätzung dazu | Hebelschein-Spekulant | |||
| So | Sonntag: BIONTECH SE ADR steht vor brisanter Weichenstellung | 17 | Maximilian Berger | ||
| So | Zelltherapie verlässt das Labor: Warum jetzt die Produktions-Revolution beginnt | Small- & Micro Cap Investment | |||
| Sa | BioNTech has reportedly contacted buyers over plans to exit German sites | 53 | Seeking Alpha | ||
| Sa | Jim Cramer Says "For the First Time in Ages, I Like Having a Position in Moderna" | 21 | Insider Monkey | ||
| Sa | Biogen Is Paying $1 Billion for a Company That Won't Say What It Makes. Here's Why That's Actually Good News for BIIB Investors. | 12 | The Motley Fool | ||
| Fr | Alvotech: Transactions of Managers and Closely Associated Persons | 6 | GlobeNewswire (USA) | ||
| Fr | Why United Therapeutics Acquired Thymmune Therapeutics For Up To $300 Million | 5 | pulse2.com | ||
| Fr | Moderna Is Up More Than 70% in a Month After a 9-0 FDA Vote. Wall Street's Average Price Target Says It Should Fall 44%. What Gives? | 27 | The Motley Fool | ||
| Fr | If You Invested $1000 In Gilead Sciences Stock 20 Years Ago, You Would Have This Much Today | 11 | Benzinga.com | ||
| Fr | ADOCIA Announces the Expiration of Exclusive Right to Negotiate Partnership for M1Pram with SANOFI | 360 | Business Wire |
Adocia retains the global rights to M1Pram and will continue to evaluate the path forward for M1Pram as the type 1 diabetes treatment landscape continues to evolve
Regulatory News:
Adocia... ► Artikel lesen | |
| Fr | United Therapeutics pays $140M for thymic cell therapy startup | 1 | FierceBiotech | ||
| Fr | Here's Why H.C. Wainwright Remains a Buy on Vanda Pharmaceuticals (VNDA) | 4 | Insider Monkey | ||
| Fr | Here's What Citi Thinks About Larimar Therapeutics (LRMR) | 5 | Insider Monkey | ||
| Fr | UTHR Strengthens Regenerative Medicine Platform With Thymmune Deal | 1 | Zacks | ||
| Fr | Should You Continue to Hold ILMN Stock in Your Portfolio? | 2 | Zacks |
1 2 3 4 5 Weiter >>
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.